Literature DB >> 14667277

Current status and future directions in breast cancer therapy.

Clifford A Hudis1.   

Abstract

With the majority of breast cancers in the United States diagnosed at an early stage, treatment is focused on cure and the prevention of relapse due to micrometastatic disease. Because systemic adjuvant therapy effectively prevents or delays some relapses and deaths in early-stage disease, this treatment approach has become widespread throughout most of the Western world. The mainstay of care for patients with breast cancer has become local therapy, consisting of surgery, radiation treatment, or both, along with adjuvant systemic therapy, which can include tamoxifen, combination chemotherapy, hormonal therapy, or a combination of these treatments. Despite this wide range of effective therapeutic interventions, therapy for metastatic disease remains focused on improving overall survival and maintaining quality of life. Future efforts are focused on improving current treatment options by optimizing dose regimens, developing effective chemotherapy combinations, using novel approaches such as HER2/neu antibody-directed therapies, and providing palliative care in the latter stages of disease.

Entities:  

Mesh:

Year:  2003        PMID: 14667277     DOI: 10.3816/cbc.2003.s.018

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  7 in total

1.  Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma.

Authors:  Tenzin Choedon; Ganeshan Mathan; Soneera Arya; Vijay L Kumar; Vijay Kumar
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.

Authors:  Chunling Ma; Qunyuan Zhang; Jian Ye; Fang Wang; Yanping Zhang; Eric Wevers; Theresa Schwartz; Pamela Hunborg; Mark A Varvares; Daniel F Hoft; Eddy C Hsueh; Guangyong Peng
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

3.  Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.

Authors:  Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe
Journal:  Biomed Opt Express       Date:  2016-08-24       Impact factor: 3.732

4.  Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.

Authors:  Wenyan Fu; Yuxiao Wang; Yunshan Zhang; Lijuan Xiong; Hiroaki Takeda; Li Ding; Qunfang Xu; Lidong He; Wenlong Tan; Augus N Bethune; Lijun Zhou
Journal:  MAbs       Date:  2014-04-16       Impact factor: 5.857

5.  Somatic mutations of the HER2 in metastatic breast cancer.

Authors:  Yi Fang; Yanxia Jiang; Xin Wang; Xue Yang; Yinqi Gao; Jing Wang
Journal:  Tumour Biol       Date:  2014-10-19

6.  CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome.

Authors:  Yi Huang; Chunling Ma; Qunyuan Zhang; Jian Ye; Fang Wang; Yanping Zhang; Pamela Hunborg; Mark A Varvares; Daniel F Hoft; Eddy C Hsueh; Guangyong Peng
Journal:  Oncotarget       Date:  2015-07-10

7.  NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy.

Authors:  F Mozaffari; C Lindemalm; A Choudhury; H Granstam-Björneklett; I Helander; M Lekander; E Mikaelsson; B Nilsson; M-L Ojutkangas; A Osterborg; L Bergkvist; H Mellstedt
Journal:  Br J Cancer       Date:  2007-06-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.